Study #2015-0529
A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL)
Study Status
Open
Treatment Agent
JCAR017
Principal Investigator
Michael Wang
Description
Unavailable
General Information
Disease Group: Lymphoma
Treatment Agent: JCAR017
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Juno Therapeutics
Study Status
IRB Review and Approval Date: 09/02/2016
Recruitment Status: Open
Projected Accrual: Up to 390
Resources and Links
Information and next steps
Disease:
Lymphoma
Study phase:
Phase I
Physician name:
Michael Wang
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-877-632-6789